ProKidney shows strong Phase 2 CKD data, FDA support, and cash runway, with key readouts ahead despite single-asset risks.

ProKidney Corp. ( NASDAQ: PROK) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT ...

A new study from Duke University School of Medicine is challenging long-standing views on blood sugar regulation—and pointing ...

Anti-obesity drugs such as semaglutide (Ozempic, Wegovy) are also promising for the treatment of alcohol use disorder and ...

The WHO has added GLP-1 agonists to its Essential Medicines List in 2025. Learn more about the impact of this decision.

GLP-1 receptor agonist drugs protect against diabetic retinopathy, a common complication of diabetes that can lead to sight ...

Dr. Bhuyan serves on the boards of both Planned Parenthood Federation of America and Planned Parenthood Global. Her areas of ...

The proportion of patients taking a GLP-1 weight-loss drug following bariatric surgery increased substantially in recent years, although the timing of initiation after surgery varied widely, a large ...

Eli Lilly is releasing new Phase 3 trial results Tuesday. Drugmaker Eli Lilly says its daily oral GLP-1 pill may help people who have obesity and people with Type 2 diabetes lose approximately 23 ...

The latest results from a trial of a pill form popular GLP-1 medications offer enough information for the Eli Lilly to request global regulatory approval this year, the company said Tuesday. The only ...

Love them or loathe them, GLP-1 drugs are fast gaining attention in the slimming space. From Novo Nordisk’s Ozempic to Eli Lilly’s Mounjaro, the trend towards injections for weight loss is growing at ...

GLP-1 RA prescriptions were associated with greater protection against uveitis compared with the cohorts taking metformin and insulin. (HealthDay News) — Glucagon-like peptide 1 receptor agonists (GLP ...